Examples of 'glucagon-like' in a sentence
Meaning of "glucagon-like"
Glucagon-like describes something that resembles or is related to glucagon, a hormone involved in carbohydrate metabolism
                                                                                            How to use "glucagon-like" in a sentence
                                        
                                        Basic
                                    
                                    
                                        
                                        Advanced
                                    
                                
                                
                                
                                glucagon-like
                                
                                
                                
                            
                            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Glucagon and glucagon-like peptide receptors as drug targets.
                                        
                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    In one aspect the peptide or protein to be acylated is a glucagon-like peptide.
                                        
                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    In one aspect an acylated glucagon-like peptide is obtained by the method of the invention.
                                        
                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    In another embodiment of the present invention the polypeptide is a glucagon-like peptide.
                                        
                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Glucagon and glucagon-like peptides have been found to have different cardiovascular effects.
                                        
                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    In one aspect of the invention the glucagon-like peptide is insulintropic.
                                        
                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    The glucagon-like peptide 1 aliquot is diluted and used in binding assays within an hour.
                                        
                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    This term also includes peptide fragments having glucagon-like activity as discussed above.
                                        
                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Glucagon and the glucagon-like peptides are encoded within a larger precursor, proglucagon.
                                        
                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Thus, there is a need for pharmaceutical compositions of glucagon-like peptides which have improved stability.
                                        
                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Insulinotropin is a glucagon-like hormone which prevents obesity by slowing down the emptying of the stomach.
                                        
                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    These considerations have strengthened our conviction to treat ischemia-reperfusion with glucagon-like peptides.
                                        
                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    In one aspect the glucagon-like peptide according to the invention is dipeptidyl aminopeptidase IV protected.
                                        
                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    In some embodiments, the enteroendocrine peptide secretion enhancing agent is a glucagon-like peptide secretion enhancing agent.
                                        
                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Promising therapeutic effects of Glucagon-like peptide 1 can be achieved only by means of continuous administration.
                                        
                                    See also
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    It is secreted alongside the hormone glucagon-like peptide 1.
                                        
                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Glucagon-like insulinotropic complexes, compositions and methods.
                                        
                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    In another embodiment of the present invention the glucagon-like peptide is exendin-4.
                                        
                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    The parent glucagon-like peptide can be produced by peptide synthesis, e . g.
                                        
                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    In another embodiment of the invention the glucagon-like peptide is a stable exendin-4 peptide.
                                        
                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    In another embodiment the peptide for use according to the invention is a mammal glucagon-like peptide-1.
                                        
                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Dulaglutide is a glucagon-like peptide-1 receptor agonist that is injected once per week.
                                        
                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    In one embodiment, the medicament includes a glucagon-like peptide-1 agonist.
                                        
                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Insulinotropic glucagon-like peptides are agonists of the GLP-1 receptor.
                                        
                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    The use according to claim 1, wherein the incretin hormone is a glucagon-like peptide-1 molecule.
                                        
                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    The agent teduglutide, which is a glucagon-like peptide-2 analog that is developed by the NPS Pharmaceuticals.
                                        
                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Glucagon-like peptide ( GLP ) agonists bind to a membrane GLP receptor.
                                        
                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    In another embodiment of the invention the glucagon-like peptide is an immunomodulated exendin-4 compound.
                                        
                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Glucagon-like peptide 1 and appetite.
                                        
                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    In another embodiment of the present invention the glucagon-like peptide is an immunomodulated exendin-4 peptide.
                                        
                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Glucagon-like peptide-2 and its therapeutic use.
                                        
                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    In another embodiment of the present invention the glucagon-like peptide is a DPPIV-protected glucagon-like peptide.
                                        
                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Glucagon-like peptide 2 receptor.
                                        
                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    In another embodiment of the present invention the glucagon-like peptide is a DPP-IV protected exendin-4 compound.
                                        
                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Glucagon-like peptide-1 derivatives and their pharmaceutical use.
                                        
                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    The physiology of glucagon-like peptide 1.
                                        
                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Exendin-4 is a homolog of the natural peptide produced in the intestine called glucagon-like peptide-1.
                                        
                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Semaglutide is a glucagon-like peptide-1 receptor agonist.
                                        
                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    In addition, short-chain fatty acids spurred an increase in Glucagon-like peptide-1 secretion.
                                        
                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Derivatives of glucagon-like peptide-2 and their therapeutic use.
                                        
                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Dapagliflozin has not been studied in combination with glucagon-like peptide 1 ( GLP-1 ) analogues.
                                        
                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Leptin and glucagon-like peptide-1 ( GLP-1 ) are peptide hormones that contribute to the regulation of appetite.
                                        
                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Human growth hormone, erythropoietin or a glucagon-like peptide 1 related peptide e . g.
                                        
                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Teduglutide is a glucagon-like peptide ( GLP-2 ), which helps the intestines absorb nutrients and fluid.
                                        
                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    As a peptidase, dipeptidyl peptidase IV in particular cleaves hormones such as glucagon-like peptide 1 ( GLP-1 ).
                                        
                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    In another embodiment, the glucagon-like peptide-1 agonist is exenatide.
                                        
                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Intracellular increases in cAMP suggested that BA may induce the secretion of glucagon-like peptide-1 ( GLP-1 ).
                                        
                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Lixisenatide is a glucagon-like peptide ( GLP1 ) receptor agonist.
                                        
                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Combinations not studied Dapagliflozin has not been studied in combination with glucagon-like peptide 1 ( GLP-1 ) analogues.
                                        
                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Human glucagon-like peptide-1 ( GLP-1 ) analogue produced by recombinant DNA technology in Saccharomyces cerevisiae.